Table II.

Associations between ZNF689 expression levels and the clinical characteristics of patients with hepatocellular carcinoma.

Characteristics	Positive expression (IRS score ≥4)	Negative expression (IRS score <4)	P-value
Sex			0.495
Male	42	51
Female	3	6
Age (years)			0.171
>60	12	30
<60	33	27
α-fetoprotein (ng/ml)			0.549
>400	24	27
<400	21	30
Hepatitis B surface antigen			0.492
Positive	45	51
Negative	0	6
HBV-DNA			0.495
>103/copies	30	30
<103/copies	15	27
Child-Pugh classification			0.764
Child A	42	54
Child B	3	3
Liver cirrhosis			0.506
Yes	33	45
No	12	12
Tumor number			0.613
Single	42	48
Multiple	3	9
Tumor size (cm)			0.028
>10	18	3
<10	27	54
Tumor size (cm)			0.104
>5	42	39
<5	3	18
Cancer embolus in portal vein			0.718
Yes	15	15
No	30	42
BCLC stage			0.410
BCLC A	3	12
BCLC B	21	27
BCLC C	21	18
Tumor capsule			0.005
Complete infiltration	6	36
No capsule infiltration	39	21
Microvascular invasion			0.037
Yes	33	18
No	12	39
Differentiation			0.273
High	3	3
Moderate	42	45
Low	0	9

BCLC, Barcelona clinic liver cancer staging; HBV, hepatitis B virus.